NCT05005845 2026-02-17
NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
NFlection Therapeutics, Inc.
Phase 2 Completed
Clinical Trials
54 trialsNCT03406208 2025-12-24
Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing
Massachusetts General Hospital
Phase NA Completed
NCT06132165 2025-11-21
Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas
Massachusetts General Hospital
Phase 1 Completed
NCT04481035 2025-07-31
NF1NAC
Children's Hospital Medical Center, Cincinnati
Phase 2 Completed
NCT00624234 2025-07-08
Neurobiology and Treatment of Reading Disability in NF-1
Vanderbilt University
Phase NA Completed
NCT03231306 2025-05-02
NF108-BINI
University of Alabama at Birmingham
Phase 2 Completed
NCT04561765 2025-03-30
Innovation in the Treatment of Persistent Pain in Adults With NF1: Implementation of the iCanCope Mobile Application- Clinical Trial
Yale University
Phase NA Completed
NCT05196854 2025-02-24
Clinical Hypnosis and Home Blood Pressure Monitoring in Children With Neurofibromatosis Type 1
Murdoch Childrens Research Institute
Phase NA Completed
NCT04730583 2025-02-21
Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas
Massachusetts General Hospital
Phase 1 Completed
NCT06120036 2025-02-21
Dosing and Tolerability of Deoxycholic Acid vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas
Massachusetts General Hospital
Phase 1 Completed
NCT01553149 2025-01-07
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
National Cancer Institute (NCI)
Phase 2 Completed
NCT02700230 2024-09-27
Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery
Mayo Clinic
Phase 1 Completed
NCT03531814 2024-06-11
Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment Trials
National Institutes of Health Clinical Center (CC)
Phase NA Completed
NCT05438290 2024-05-06
DPCP to Treat Cutaneous Neurofibromas Associated With NF1
Icahn School of Medicine at Mount Sinai
Phase 1 Completed
NCT03326388 2024-04-04
INSPECT
Great Ormond Street Hospital for Children NHS Foundation Trust
Phase 1/2 Completed
NCT03433183 2023-12-26
SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
Sarcoma Alliance for Research through Collaboration
Phase 2 Completed
NCT02332902 2023-12-20
DCLNF1
The University of Texas Health Science Center, Houston
Phase 2 Completed
NCT02839720 2023-12-06
Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma
National Cancer Institute (NCI)
Phase 2 Completed
NCT05377008 2023-09-22
OPTIMAL-SSI
Virginia Commonwealth University
Phase NA Completed
NCT00846430 2023-08-30
Medical Treatment of "High-Risk" Neurofibromas
Corewell Health West
Phase 2 Completed
NCT04495127 2023-04-26
Selumetinib Paediatric NF1 Japan Study
AstraZeneca
Phase 1 Completed
NCT04435665 2022-08-09
NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
NFlection Therapeutics, Inc.
Phase 2 Completed
NCT02471339 2022-06-14
Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain
National Institutes of Health Clinical Center (CC)
Phase 3 Completed
NCT02415153 2022-04-25
Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT02944032 2022-03-03
COGTRAIN
Children's National Research Institute
Phase NA Completed
NCT04991428 2021-08-05
Mechanism of Action of Transcranial Direct Current Stimulation in Neurofibromatosis Type 1
University of Manchester
Phase NA Completed
NCT03826940 2021-04-02
ASD/NF1inhib
University of Coimbra
Phase NA Completed
NCT01058330 2021-03-23
Effects of Physical Training on Bone and Muscle Quality, Muscle Strength, and Motor Coordination in Children With NF1
Shriners Hospitals for Children
Phase NA Completed
NCT03672838 2021-03-18
A Single Center Pilot Study to Assess the Intra-observer Reliability of Measuring Muscle Strength Using a Hand Held Dynamometer in Children and Adults With Neurofibromatosis Type 1 (NF1) and Type 2 (NF2)
NYU Langone Health
Phase NA Completed
NCT03888248 2021-03-16
Whole-body Vibration in Children With Neurofibromatosis Type 1
Manchester University NHS Foundation Trust
Phase NA Completed
NCT01125046 2021-01-22
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Northwestern University
Phase 2 Completed
NCT00727233 2019-12-12
Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03310996 2019-04-24
tDCS is NF1
University of Manchester
Phase NA Completed
NCT02096471 2019-01-10
MEK Inhibitor
University of Alabama at Birmingham
Phase 2 Completed
NCT03649165 2018-11-08
A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants
AstraZeneca
Phase 1 Completed
NCT00304083 2018-09-18
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors
Sarcoma Alliance for Research through Collaboration
Phase 2 Completed
NCT00030264 2018-08-08
Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas
Children's Hospital of Philadelphia
Phase 2 Completed
NCT00076102 2018-04-23
Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00021541 2018-04-17
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00853580 2018-03-12
STARS
University of Alabama at Birmingham
Phase 2 Completed
NCT00634270 2017-11-17
Protocol 102
University of Alabama at Birmingham
Phase 2 Completed
NCT03090971 2017-10-26
Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1
Fundação Educacional Serra dos Órgãos
Phase 2 Completed
NCT00865644 2017-01-10
Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1
Massachusetts General Hospital
Phase 1 Completed
NCT00352599 2016-11-22
NF1
University of California, Los Angeles
Phase 1 Completed
NCT00657202 2016-07-07
Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1
Massachusetts General Hospital
Phase EARLY_PHASE1 Completed
NCT01851135 2016-07-06
NF1-QDV
Nantes University Hospital
Phase NA Completed
NCT02298270 2016-06-23
Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype
Massachusetts General Hospital
Phase NA Completed
NCT00589784 2016-01-25
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02422732 2015-08-19
Functional Imaging and Reading Deficit in Children With NF1
University Hospital, Toulouse
Phase NA Completed
NCT00053937 2015-04-30
Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas
National Cancer Institute (NCI)
Phase 1 Completed